NASDAQ:ALNY

Alnylam Pharmaceuticals Stock Forecast, Price & News

$190.20
+2.72 (+1.45 %)
(As of 09/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$185.97
$191.86
50-Day Range
$170.34
$207.73
52-Week Range
$119.29
$209.73
Volume323,891 shs
Average Volume633,970 shs
Market Capitalization$22.60 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.22
30 days | 90 days | 365 days | Advanced Chart
Receive ALNY News and Ratings via Email

Sign-up to receive the latest news and ratings for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Alnylam Pharmaceuticals logo

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. The firm's products include ONPATTRO, GIVLAARI, and OXLUMO. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links


MarketRank

Overall MarketRank

2.07 out of 5 stars

Medical Sector

478th out of 1,352 stocks

Pharmaceutical Preparations Industry

235th out of 665 stocks

Analyst Opinion: 2.2Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Alnylam Pharmaceuticals (NASDAQ:ALNY) Frequently Asked Questions

Is Alnylam Pharmaceuticals a buy right now?

15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last twelve months. There are currently 8 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Alnylam Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALNY, but not buy additional shares or sell existing shares.
View analyst ratings for Alnylam Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Alnylam Pharmaceuticals?

Wall Street analysts have given Alnylam Pharmaceuticals a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Alnylam Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals saw a increase in short interest in July. As of July 30th, there was short interest totaling 5,060,000 shares, an increase of 19.9% from the July 15th total of 4,220,000 shares. Based on an average daily trading volume, of 653,200 shares, the short-interest ratio is currently 7.7 days.
View Alnylam Pharmaceuticals' Short Interest
.

When is Alnylam Pharmaceuticals' next earnings date?

Alnylam Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Alnylam Pharmaceuticals
.

How were Alnylam Pharmaceuticals' earnings last quarter?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) posted its quarterly earnings data on Monday, August, 2nd. The biopharmaceutical company reported ($1.61) earnings per share for the quarter, meeting the Zacks' consensus estimate of ($1.61). The biopharmaceutical company earned $220.55 million during the quarter, compared to the consensus estimate of $193.66 million. Alnylam Pharmaceuticals had a negative net margin of 128.96% and a negative trailing twelve-month return on equity of 88.43%. The firm's quarterly revenue was up 112.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($1.67) EPS.
View Alnylam Pharmaceuticals' earnings history
.

How has Alnylam Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

Alnylam Pharmaceuticals' stock was trading at $101.89 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ALNY stock has increased by 86.7% and is now trading at $190.20.
View which stocks have been most impacted by COVID-19
.

What guidance has Alnylam Pharmaceuticals issued on next quarter's earnings?

Alnylam Pharmaceuticals updated its FY 2021 earnings guidance on Tuesday, August, 10th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $790 million-$865 million, compared to the consensus revenue estimate of $837.45 million.

What price target have analysts set for ALNY?

15 analysts have issued 12 month target prices for Alnylam Pharmaceuticals' shares. Their forecasts range from $47.00 to $250.00. On average, they expect Alnylam Pharmaceuticals' stock price to reach $169.33 in the next twelve months. This suggests that the stock has a possible downside of 11.0%.
View analysts' price targets for Alnylam Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Alnylam Pharmaceuticals' key executives?

Alnylam Pharmaceuticals' management team includes the following people:

What is John M. Maraganore's approval rating as Alnylam Pharmaceuticals' CEO?

65 employees have rated Alnylam Pharmaceuticals CEO John M. Maraganore on Glassdoor.com. John M. Maraganore has an approval rating of 99% among Alnylam Pharmaceuticals' employees. This puts John M. Maraganore in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Alnylam Pharmaceuticals' key competitors?

What other stocks do shareholders of Alnylam Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alnylam Pharmaceuticals investors own include Alibaba Group (BABA), NVIDIA (NVDA), XOMA (XOMA), Ionis Pharmaceuticals (IONS), Gilead Sciences (GILD), NXP Semiconductors (NXPI), Mylan (MYL), AbbVie (ABBV), Micron Technology (MU) and Advanced Micro Devices (AMD).

What is Alnylam Pharmaceuticals' stock symbol?

Alnylam Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNY."

Who are Alnylam Pharmaceuticals' major shareholders?

Alnylam Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include FMR LLC (14.84%), Vanguard Group Inc. (8.83%), Baillie Gifford & Co. (8.70%), BlackRock Inc. (7.32%), Price T Rowe Associates Inc. MD (4.65%) and Dodge & Cox (4.56%). Company insiders that own Alnylam Pharmaceuticals stock include Akshay Vaishnaw, Barry E Greene, Jeffrey W Dunn, John Maraganore, Laurie Keating, Marsha Fanucci, Phillip A Sharp, Steven M Paul and Yvonne Greenstreet.
View institutional ownership trends for Alnylam Pharmaceuticals
.

Which major investors are selling Alnylam Pharmaceuticals stock?

ALNY stock was sold by a variety of institutional investors in the last quarter, including Maverick Capital Ltd., Point72 Asset Management L.P., BlackRock Inc., APG Asset Management N.V., Invesco Ltd., Blackstone Inc, Bridger Management LLC, and Vanguard Group Inc.. Company insiders that have sold Alnylam Pharmaceuticals company stock in the last year include Akshay Vaishnaw, Jeffrey W Dunn, John Maraganore, Laurie Keating, Phillip A Sharp, Steven M Paul, and Yvonne Greenstreet.
View insider buying and selling activity for Alnylam Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Alnylam Pharmaceuticals stock?

ALNY stock was acquired by a variety of institutional investors in the last quarter, including Jefferies Group LLC, Dodge & Cox, Ikarian Capital LLC, Amundi, Balyasny Asset Management LLC, State Street Corp, The Manufacturers Life Insurance Company , and Baillie Gifford & Co..
View insider buying and selling activity for Alnylam Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Alnylam Pharmaceuticals?

Shares of ALNY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alnylam Pharmaceuticals' stock price today?

One share of ALNY stock can currently be purchased for approximately $190.20.

How much money does Alnylam Pharmaceuticals make?

Alnylam Pharmaceuticals has a market capitalization of $22.60 billion and generates $492.85 million in revenue each year. The biopharmaceutical company earns $-858,280,000.00 in net income (profit) each year or ($7.46) on an earnings per share basis.

How many employees does Alnylam Pharmaceuticals have?

Alnylam Pharmaceuticals employs 1,453 workers across the globe.

When was Alnylam Pharmaceuticals founded?

Alnylam Pharmaceuticals was founded in 2002.

What is Alnylam Pharmaceuticals' official website?

The official website for Alnylam Pharmaceuticals is www.alnylam.com.

Where are Alnylam Pharmaceuticals' headquarters?

Alnylam Pharmaceuticals is headquartered at 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142.

How can I contact Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals' mailing address is 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at (617) 551-8200 or via email at [email protected]


This page was last updated on 9/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.